Startups
Highland Therapeutics Inc. is an emerging pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technologies to optimize the delivery of previously approved drug products.
The Company's lead products, HLD-100 and HLD-200, are novel formulations of the psychostimulants (amphetamine and methylphenidate, respectively) used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease - the lack of symptom control during the early morning routine. The clinically meaningful benefits of Highland's approach are targeted at helping ADHD patients and their families improve the quality of their lives.
Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services
group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them
commercialize their ideas and build globally competitive companies.
The Company's lead products, HLD-100 and HLD-200, are novel formulations of the psychostimulants (amphetamine and methylphenidate, respectively) used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease - the lack of symptom control during the early morning routine. The clinically meaningful benefits of Highland's approach are targeted at helping ADHD patients and their families improve the quality of their lives.
Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services
group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them
commercialize their ideas and build globally competitive companies.
Overview
Location
Canada, Ontario, Toronto
Employees
51-200
Total raised
$344.7M
Founded date
2008
Funding Rounds 4
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jun 24, 2015 | Funding round | $50M | |
| Oct 16, 2014 | Funding round | $25M | |
| Aug 16, 2013 | Funding round | $6.7M |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 27, 2017 | Innovation in ADHD: Is it just more of the same? | Released Friday, the authors project an 8.5 percent compound annual growth rate (CAGR) over the next seven years, driven by increased awareness and a greater willingness to treat the condition with drugs, especially in the adult population.... |
| Jan 24, 2017 | Highland Therapeutics raises $263 million through Morgan Stanley to commercialize ADHD drug | Highland Therapeutics, the parent company of Ironshore Pharmaceuticals, has secured a $263 million private placement due by 2024. Morgan Stanley acted as sole placement agent for the transaction. Based at MaRS in Toronto, Highland plans to ... |
| Jun 24, 2015 | Highland Therapeutics Completes US$50M Financing | Highland Therapeutics Inc., a Toronto, Canada-based pharmaceutical company, completed a US$50m financing. It consists of a US$25m offering of Class A Common Shares led by Eastern Capital Limited and a US$25m credit facility provided by Citi... |
| Oct 16, 2014 | Highland Therapeutics Closes $25M in Funding | Highland Therapeutics, a Toronto, Canada-based pharmaceutical company, closed a $25m in funding. The backer was was an unnamed private equity investor. The company intends to use the funds, through its wholly owned subsidiary Ironshore Phar... |
| Aug 16, 2013 | Highland Therapeutics Completes US$6.7M Financing | Highland Therapeutics Inc., a Toronto, CA-based specialty pharmaceutical company, completed a US$6.7m funding. Investors included Highland’s Clinical Development group – an entity responsible for the manufacturing and clinical development o... |
| Innovation in ADHD: Is it just more of the same? | The future looks bright for companies targeting attention-deficit hyperactivity disorder (ADHD) according to a new Research and Markets report, which predicts sales in the seven major markets (7MM) will steadily rise from $6.1 billion in 20... |
Reviews 0
FAQ about Highland Therapeutics
When was Highland Therapeutics founded?
Highland Therapeutics was founded in 2008.
How much funding has Highland Therapeutics raised?
Highland Therapeutics has raised $344.7M in total across 4 funding rounds.
What funding rounds has Highland Therapeutics raised?
Parsers VC lists 4 funding rounds of Highland Therapeutics, among them a funding round of $50M on Jun 24, 2015, a funding round of $25M on Oct 16, 2014 and a funding round of $6.7M on Aug 16, 2013.
What has the press written about Highland Therapeutics?
Parsers VC has collected 7 articles mentioning Highland Therapeutics, among them “Innovation in ADHD: Is it just more of the same?” (Jan 27, 2017) and “Highland Therapeutics raises $263 million through Morgan Stanley to commercialize ADHD drug” (Jan 24, 2017).
Is Highland Therapeutics still active?
Yes, Highland Therapeutics is active; its latest activity on Parsers VC dates from Jan 27, 2017.